バイオシミュレーション市場：オファリング、デリバリーモデル、エンドユーザー、アプリケーション別-2024-2030年の世界予測

バイオシミュレーション市場規模は2023年に38億1,000万米ドルと推定され、2024年には44億米ドルに達し、CAGR 14.55％で2030年には98億7,000万米ドルに達すると予測されています。

バイオシミュレーションは、数学、生物学、コンピュータプログラミングを組み合わせてシミュレーションを作成し、仮説の検証、結果の予測、バイオテクノロジーの新たな可能性の探求を行う。バイオシミュレーションは、遺伝子発現、代謝、細胞成長などの生物学的現象をシミュレーションすることで、研究者が生命の複雑さをより深く理解し、ヘルスケアのための新製品を開発するのに役立っています。新薬や医薬品の開発が進み、製薬・バイオ医薬品分野におけるデジタル化技術の統合に政府が力を入れるようになったことで、バイオシミュレーションシステムのニーズが高まっています。しかし、バイオシミュレーションソフトウェアの開発には高いコストがかかるため、市場成長の妨げとなっています。コンピュータ支援設計（CAD）と仮想現実（VR）技術の統合が進むとともに、新しいバイオシミュレーションソフトウェアの開発における人工知能（AI）と機械学習（ML）の進歩により、バイオシミュレーション市場の拡大が見込まれています。

提供モデル構築、シミュレーション、解析、可視化のプラットフォームを提供するバイオシミュレーションのソフトウェア利用が増加

受託サービスは、バイオシミュレーションの専門知識を顧客に提供する専門企業や研究組織によって提供され、モデル開発、シミュレーション研究、データ分析、解釈を支援します。インハウスサービスは、組織や研究機関内で行われるバイオシミュレーションサービスです。分子モデリング＆シミュレーションソフトウェアは、タンパク質、核酸、低分子などの分子の挙動のシミュレーションとモデリングに重点を置いています。分子間の相互作用や構造変化を研究し、結合親和性などの特性を予測するために使用されます。PBPKモデリング＆シミュレーションソフトウェアは、薬物や化学物質の体内分布、吸収、代謝、排泄をシミュレーションするために設計されています。PK/PD、モデリング＆シミュレーションソフトウェアは、薬物の薬物動態学的および薬力学的特性に影響を与え、薬物濃度および曝露反応関係の予測を支援し、投与レジメンを最適化します。毒性予測ソフトウェアは、化学化合物の潜在的な毒性を予測することに重点を置いています。計算モデルを使用して、特定の化学物質や薬剤への曝露の安全性と潜在的リスクを評価します。臨床試験デザインソフトウェアは、臨床試験のデザインと最適化を支援し、臨床試験の効率と妥当性を改善するために、さまざまな臨床試験シナリオのシミュレーション、統計的検出力の評価、サンプルサイズの最適化を行う。

デリバリーモデル：バイオシミュレーションでは、ユーザーに完全なコントロールを提供するオーナーシップモデルが好まれる傾向にあります。

バイオシミュレーションの所有権モデルでは、ユーザーはソフトウェアとサービスを購入し、ソフトウェアとその使用方法を完全にコントロールすることができます。バイオシミュレーション所有モデルでは、ユーザーはソフトウェアの永久ライセンスを購入し、無期限に使用する権利を付与されます。サブスクリプションモデルでは、ユーザーはソフトウェアやサービスにアクセスし、使用するために定期的な料金を支払います。このモデルでは、ユーザーは通常ソフトウェアを所有しないが、最新バージョンやアップデートに継続的にアクセスできます。

エンドユーザー：製薬会社やバイオテクノロジー企業におけるバイオシミュレーションの採用拡大

医薬品開発業務受託機関（CRO）は、顧客の創薬・研究開発プロセスをサポートするためにバイオシミュレーションを活用することが多く、バイオシミュレーションの技術を用いた分子モデリング、PK/PDモデリング、毒性予測、試験デザインなどのサービスを提供しています。製薬会社やバイオテクノロジー企業は、医薬品開発パイプラインを通じてバイオシミュレーションを幅広く採用しています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）をはじめとする規制当局は、医薬品の安全性と有効性を評価した上で上市を承認するという重要な役割を担っています。規制当局はバイオシミュレーションを用いて、医薬品のリスク・ベネフィット・プロファイルを評価し、試験デザインを最適化し、医薬品承認プロセスにおいて十分な情報に基づいた意思決定を行います。学術機関や政府機関などの調査機関は、科学的知識の向上や高度な研究を行うためにバイオシミュレーションを使用します。研究者はバイオシミュレーションのツールやテクニックを利用して、複雑な生物学的システムのモデル化やシミュレーションを行い、仮説を探求し、基本的な生物学的プロセスについて洞察を深めています。

応用医薬品開発へのバイオシミュレーションの応用拡大

バイオシミュレーションは、薬物の薬物動態（PK）および薬力学（PD）特性に関する洞察や予測を提供し、投与レジメンの最適化、標的組織における薬物濃度の予測、薬剤候補の潜在的な有効性と安全性の評価を支援することにより、医薬品開発において重要な役割を果たしています。PBPKやPK/PDモデリングなどのバイオシミュレーションの技術は、医薬品開発において十分な情報に基づいた意思決定を支援します。バイオシミュレーションは臨床試験のデザインと最適化をサポートし、医薬品や化合物の吸収、分布、代謝、排泄、毒性特性の予測と評価を可能にします。バイオシミュレーションは、医薬品開発プロセスの早い段階でADME/Toxの潜在的な問題を特定し、大規模な動物実験の必要性を減らし、潜在的なリスクに関する洞察を提供します。PK/PDモデリングとシミュレーションにより、薬物曝露と反応性の関係を予測することができます。バイオシミュレーションは、分子モデリングとシミュレーション技術を採用することで、リード化合物の同定と最適化をサポートします。潜在的な薬剤候補のスクリーニングと評価、標的分子への結合親和性の予測、効力と選択性を向上させるための化学構造の最適化を支援します。バイオシミュレーション技術は、潜在的な創薬標的の同定と検証に役立ちます。バイオシミュレーションは、薬剤分子と標的タンパク質間の相互作用をモデル化しシミュレーションすることで、特定のタンパク質を標的とすることの実現可能性や潜在的な有効性を評価するのに役立ちます。

地域別インサイト

南北アメリカ地域は、バイオシミュレーション市場が非常に発展している地域です。これは、米国に主要な既存プレーヤーが存在し、バイオシミュレーションソフトウェアを発展させる努力を続けているためです。FDA（米国食品医薬品局）、EMA（欧州医薬品庁）、カナダ保健省など、医薬品開発や臨床試験の安全性と効率性を確保するための規制当局が確立していることが、南北アメリカ、欧州、アジア太平洋地域の市場成長に寄与しています。EMEA地域を考慮すると、英国、ドイツ、フランスにおける医薬品開発と臨床試験への投資の増加が、バイオシミュレーションソフトウェア＆サービスの採用を拡大しています。アジア太平洋地域における慢性疾患の増加は、政府や規制当局による医薬品開発のための資金提供活動の拡大を促し、バイオシミュレーション市場開拓のためのプラットフォームとなることが期待されています。オーストラリアの創薬イニシアティブや医学研究商業化イニシアティブなど、医薬研究開発（R&D）活動を目的とした様々なイニシアティブの存在が、アジア太平洋におけるバイオシミュレーションの利用を拡大しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはバイオシミュレーション市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、バイオシミュレーション市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.バイオシミュレーション市場の市場規模および予測は？

2.バイオシミュレーション市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.バイオシミュレーション市場の技術動向と規制枠組みは？

4.バイオシミュレーション市場における主要ベンダーの市場シェアは？

5.バイオシミュレーション市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 個別化医療の調査への重点化
    • 安全な医薬品の開発を促進するためのバイオシミュレーションの使用に対する規制当局の承認
  • 抑制要因
    • バイオシミュレーションのインストールと技術開発に関わる価格の引き上げ
  • 機会
    • 新しい生物学的療法を強化するためのシミュレーションソリューションの継続的な進歩
    • 医薬品開発と医薬品試験への投資増加
  • 課題
    • 正確な結果を生み出すための複雑さと認識の欠如
• 市場セグメンテーション分析
  • 提供内容：バイオシミュレーションにおけるソフトウェアの使用が増加し、モデル構築、シミュレーション、分析、視覚化のためのプラットフォームが提供される
  • 配信モデル：ユーザーに完全な制御を提供するためのバイオシミュレーションでの所有権モデルが好まれる傾向が高まっています
  • エンドユーザー：製薬・バイオテクノロジー企業におけるバイオシミュレーションの採用拡大
  • 応用：医薬品開発におけるバイオシミュレーションの応用拡大
• 市場動向分析
  • 南北アメリカにおけるバイオシミュレーションの使用拡大に向けた医薬品開発および共同活動への多額の投資
  • アジア太平洋地域の医薬品調査における革新的技術の導入を促進する政府の取り組み
  • 臨床試験と医薬品開発活動の増加により、EMEA地域でバイオシミュレーションの範囲が拡大
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 バイオシミュレーション市場：提供別

• サービス
• ソフトウェア

第7章 バイオシミュレーション市場配信モデル別

• 所有権モデル
• サブスクリプションモデル

第8章 バイオシミュレーション市場：エンドユーザー別

• 契約調査機関
• 製薬・バイオテクノロジー企業
• 規制当局
• 調査機関

第9章 バイオシミュレーション市場：用途別

• 医薬品開発
• 創薬

第10章 南北アメリカのバイオシミュレーション市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のバイオシミュレーション市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのバイオシミュレーション市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • CertaraとDNDiが提携し、データ提出を迅速化し、治療が遅れている患者への医薬品承認を加速
  • Certaraが医薬品開発向けPhoenixバイオシミュレーションソフトウェアのバージョン8.4をリリース
  • Certara社、医薬品発見のためのAIを活用してCODEXプラットフォームの機能を強化
  • Simulations Plusが、医薬品開発の効率化と患者の転帰改善を目的とした新しい統合肺ソフトウェアおよびサービスパッケージを発表
  • Simulations PlusがDILIsymソフトウェアライセンスの米国FDA更新を取得
  • Simulations PlusがAI/ML技術を応用して新規化合物を設計するパートナーシップを締結
  • Simulations Plusが再設計されたNAFLDsym QSPソフトウェアツールをリリース
  • セルワークス、がん治療薬の開発を加速し、棚上げされていた医薬品資産を復活させるため、精密医薬品事業に進出
  • Certaraが科学的イノベーションを加速する予測を提供する人工知能企業Vyasaを買収
  • Applied BioMath LLCがSpringWorks Therapeutics社と多発性骨髄腫のシステム薬理学モデリングに関する提携を発表
  • Applied BioMath LLCは、炎症性腸疾患のシステム薬理学モデリングにおけるCelsius Therapeuticsとの協力関係の継続を発表
  • GNSとセルヴィエ、多発性骨髄腫治療薬の発見と臨床開発を推進するAI連携を発表
  • ケイデンス、計算分子設計の先駆的リーダーであるOpenEye Scientificの買収により分子シミュレーション分野に進出
  • レゾリューション・メディカルがライフテック・グループを買収
  • カラコンベンチャーズ、AI駆動型バイオシミュレーション企業VeriSIM Lifeに投資

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BIOSIMULATION MARKET RESEARCH PROCESS
• FIGURE 2. BIOSIMULATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BIOSIMULATION MARKET DYNAMICS
• FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 81. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 84. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 85. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 86. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 87. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 88. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 89. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 90. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 93. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 94. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 95. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 96. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 97. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 98. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 99. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 102. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 103. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 104. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 105. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 106. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 107. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 108. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 109. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 110. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 111. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 112. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 113. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 114. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 115. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 116. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 117. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 122. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 123. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 124. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 125. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 126. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 127. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 128. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 129. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 130. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 131. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 132. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 133. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 134. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 135. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 136. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 137. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 138. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 139. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 140. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 141. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 142. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 143. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 144. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 145. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 146. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 147. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 148. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 149. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 150. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 151. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 152. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 153. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 158. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 159. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 160. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 161. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 162. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 163. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 164. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 165. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 166. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 167. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 168. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 169. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 170. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 171. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 172. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 173. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 176. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 177. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 178. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 179. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 180. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 181. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 182. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 183. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 184. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 185. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 186. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 187. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 188. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 189. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 190. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 191. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 192. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 193. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 194. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 195. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 196. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 197. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 198. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 199. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 200. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 201. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 202. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 203. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 204. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 205. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 206. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 207. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 208. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 209. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 210. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 211. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 212. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 213. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 216. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 217. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 218. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 219. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 220. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 221. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 222. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 223. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 224. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 225. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 226. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 227. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 228. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 229. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 230. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 231. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 234. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 235. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 236. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 237. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 238. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 239. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 240. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 241. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 242. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 243. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 244. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 245. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 246. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 247. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 248. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 249. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 252. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 253. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 254. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 255. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 256. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 257. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 258. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 259. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 260. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 261. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 262. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 263. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 264. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 265. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 266. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 267. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 270. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 271. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 272. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 273. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 274. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 275. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 276. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 277. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 278. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 279. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 280. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 281. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 282. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 283. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 284. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 285. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 288. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 289. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 290. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 291. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 292. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 293. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 294. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 295. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 296. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 297. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 298. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 299. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 300. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 301. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 302. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 303. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 304. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 305. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 306. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 307. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 308. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 309. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 310. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 311. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 312. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 313. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 314. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 315. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 316. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 317. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 318. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 319. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 320. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 321. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 322. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 323. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 324. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 325. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 326. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 327. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 328. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 329. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 330. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 331. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 332. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 333. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 334. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 335. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 336. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 337. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 338. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 339. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 340. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 341. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 342. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 343. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 344. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 345. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 346. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 347. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 348. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 349. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 350. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 351. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
• TABLE 352. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
• TABLE 353. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
• TABLE 354. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
• TABLE 355. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 356. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 357. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 358. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 359. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 360. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 361. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
• TABLE 362. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
• TABLE 363. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
• TABLE 364. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
• TABLE 365. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 366. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING,

[197 Pages Report] The Biosimulation Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.40 billion in 2024, at a CAGR 14.55% to reach USD 9.87 billion by 2030.

Biosimulation combines mathematics, biology, and computer programming to create simulations to test hypotheses, predict outcomes, and explore new possibilities in biotechnology. By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.

Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization

Contract services are provided by specialized companies and research organizations that offer biosimulation expertise to clients, which assist with model development, simulation studies, data analysis, and interpretation. In-house services are biosimulation services conducted within an organization and research institution. Molecular modeling & simulation software focuses on simulating and modeling the behavior of molecules, such as proteins, nucleic acids, and small molecules. It is used to study molecular interactions and conformational changes and predict properties such as binding affinity. PBPK modeling & simulation software is designed to simulate the distribution, absorption, metabolism, and excretion of drugs and chemicals in the body. PK/PD, modeling & simulation software, affects drugs' pharmacokinetic and pharmacodynamic properties, helps predict drug concentrations and exposure-response relationships, and optimizes dosing regimens. Toxicity prediction software focuses on predicting the potential toxicity of chemical compounds. It uses computational models to assess the safety and potential risks of exposure to specific chemicals or drugs. Trial design software helps in the design and optimization of clinical trials and also simulates different trial scenarios, evaluates statistical power, and optimizes sample sizes to improve the efficiency and validity of clinical studies.

Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users

In the biosimulation ownership model, users purchase the software and service outright, giving them full control over the software and its usage. In the biosimulation ownership model, users purchase a perpetual license for the software, granting them the right to use it indefinitely. Subscription models involve users paying a recurring fee to access and use the software or services. With this model, users usually do not own the software but have ongoing access to the latest versions and updates.

End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies

Contract research organizations (CROs) often utilize biosimulation to support their clients' drug discovery and development processes and offer services such as molecular modeling, PK/PD modeling, toxicity prediction, and trial design using biosimulation techniques. Pharmaceutical & biotechnology companies extensively employ biosimulation throughout the drug development pipeline. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in evaluating drug safety and effectiveness before being approved for market release. Regulatory authorities use biosimulation to assess the risk-benefit profile of drugs, optimize study designs, and make informed decisions during the drug approval process. Research institutes, including academic institutions and government organizations, employ biosimulation to advance scientific knowledge and conduct advanced research. Researchers utilize biosimulation tools and techniques to model and simulate complex biological systems, explore hypotheses, and gain insights into fundamental biological processes.

Application: Increasing application of biosimulation for drug development

Biosimulation plays a vital role in drug development by providing insights and predictions related to drug pharmacokinetic (PK) and pharmacodynamic (PD) properties, assisting in optimizing dosing regimens, predicting drug concentrations in target tissues, and assessing drug candidates' potential efficacy and safety. Biosimulation techniques, such as PBPK and PK/PD modeling, aid in making informed decisions during drug development. Biosimulation supports the design and optimization of clinical trials and enables the prediction and evaluation of drugs and chemical compounds' absorption, distribution, metabolism, excretion, and toxicity properties. Biosimulation helps identify potential ADME/Tox issues early in the drug development process, reducing the need for extensive animal testing and providing insights into potential risks. PK/PD modeling and simulation assist in predicting the relationship between drug exposure and response. Biosimulation supports lead identification & optimization by employing molecular modeling and simulation techniques. It aids in screening and evaluating potential drug candidates, predicting their binding affinity to target molecules, and optimizing their chemical structures for improved potency and selectivity. Biosimulation techniques aid in the identification and validation of potential drug targets. By modeling and simulating the interactions between drug molecules and target proteins, biosimulation helps evaluate the feasibility and potential effectiveness of targeting specific proteins.

Regional Insights

The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Offering
  • Services
    • Contract Services
    • In-House Services

• Software
  • Molecular Modeling & Simulation Software
  • PBPK Modeling & Simulation Software
  • PK/PD Modeling & Simulation Software
  • Toxicity Prediction Software
  • Trial Design Software
• Delivery Model
  • Ownership Models
  • Subscription Models

• End-User
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Regulatory Authorities
  • Research Institutes

• Application
  • Drug Development
    • Clinical Trials
    • Preclinical Testing
      • ADME/Tox
      • PK/PD
  • Drug Discovery
    • Lead Identification & Optimization
    • Target Identification & Validation
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biosimulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimulation Market?

3. What are the technology trends and regulatory frameworks in the Biosimulation Market?

4. What is the market share of the leading vendors in the Biosimulation Market?

5. Which modes and strategic moves are suitable for entering the Biosimulation Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing emphasis on research of personalized medicine
    • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
    • 5.1.3.2. Rising investments for drug developments and drug testings
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
  • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
  • 5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
  • 5.2.4. Application: Increasing application of biosimulation for drug development
• 5.3. Market Trend Analysis
  • 5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
  • 5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
  • 5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis

6. Biosimulation Market, by Offering

• 6.1. Introduction
• 6.2. Services
• 6.3. Software

7. Biosimulation Market, by Delivery Model

• 7.1. Introduction
• 7.2. Ownership Models
• 7.3. Subscription Models

8. Biosimulation Market, by End-User

• 8.1. Introduction
• 8.2. Contract Research Organizations
• 8.3. Pharmaceutical & Biotechnology Companies
• 8.4. Regulatory Authorities
• 8.5. Research Institutes

9. Biosimulation Market, by Application

• 9.1. Introduction
• 9.2. Drug Development
• 9.3. Drug Discovery

10. Americas Biosimulation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Biosimulation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
  • 13.3.2. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
  • 13.3.3. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
  • 13.3.4. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
  • 13.3.5. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
  • 13.3.6. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
  • 13.3.7. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
  • 13.3.8. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
  • 13.3.9. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
  • 13.3.10. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
  • 13.3.11. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
  • 13.3.12. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
  • 13.3.13. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
  • 13.3.14. Resolution Medical Acquires LifeTec Group
  • 13.3.15. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio